Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Saint-Louis Hospital & Paris Diderot University

The growing role of combination approaches in MF & agents being explored 2:31
The growing role of combination approaches in MF & agents being explored
Jean-Jacques Kiladjian • 9 Oct 2023
Ruxolitinib combinations in patients with myelofibrosis 2:14
Ruxolitinib combinations in patients with myelofibrosis
Jean-Jacques Kiladjian • 26 Apr 2023
The role of allogeneic transplantation in myelofibrosis & patient eligibility for alloSCT 1:34
The role of allogeneic transplantation in myelofibrosis & patient eligibility for alloSCT
Jean-Jacques Kiladjian • 26 Apr 2023
Approved & emerging JAK inhibitors for patients with high-risk MF who are transplant-ineligible 2:09
Approved & emerging JAK inhibitors for patients with high-risk MF who are transplant-ineligible
Jean-Jacques Kiladjian • 26 Apr 2023
The impact of early ruxolitinib treatment on OS in the COMFORT-I and COMFORT-II studies 1:20
The impact of early ruxolitinib treatment on OS in the COMFORT-I and COMFORT-II studies
Jean-Jacques Kiladjian • 26 Apr 2023
The importance of genomic testing in MPNs 1:19
The importance of genomic testing in MPNs
Jean-Jacques Kiladjian • 22 Aug 2022
Calreticulin-directed vaccines how they may impact MPN treatment 1:32
Calreticulin-directed vaccines how they may impact MPN treatment
Jean-Jacques Kiladjian • 22 Aug 2022
Updates on ropeginterferon in MPNs 1:41
Updates on ropeginterferon in MPNs
Jean-Jacques Kiladjian • 22 Aug 2022
The role of navtemadlin in the MPN treatment landscape 0:56
The role of navtemadlin in the MPN treatment landscape
Jean-Jacques Kiladjian • 22 Aug 2022
Agents of interest being explored in essential thrombocythemia and polycythemia vera 1:26
Agents of interest being explored in essential thrombocythemia and polycythemia vera
Jean-Jacques Kiladjian • 22 Aug 2022
An update on imetelstat in R/R myelofibrosis 1:44
An update on imetelstat in R/R myelofibrosis
Jean-Jacques Kiladjian • 16 May 2022
Ongoing trials in polycythemia vera: Low-PV & VERIFY 1:54
Ongoing trials in polycythemia vera: Low-PV & VERIFY
Jean-Jacques Kiladjian • 16 May 2022
Drugs under investigation for patients with MF who have failed treatment with JAK inhibitors 1:15
Drugs under investigation for patients with MF who have failed treatment with JAK inhibitors
Jean-Jacques Kiladjian • 16 May 2022
Recent advances in eosinophilia with FGFR rearrangement 1:18
Recent advances in eosinophilia with FGFR rearrangement
Jean-Jacques Kiladjian • 16 May 2022
The role of red cell mass measurement in the diagnosis of polycythemia vera 2:30
The role of red cell mass measurement in the diagnosis of polycythemia vera
Jean-Jacques Kiladjian • 16 May 2022
Characteristics and outcomes of young patients with MPNs 2:22
Characteristics and outcomes of young patients with MPNs
Jean-Jacques Kiladjian • 16 May 2022
The content of VJHemOnc is intended for healthcare professionals